Some workers who are approaching retirement may need to change their plans thanks to President Donald Trump’s “One Big Beautiful Bill” — including when they retire. Due to the introduction of new work requirements for Medicaid and the Supplemental Nutrition Assistance Program (SNAP), Americans may need to remain in the workforce longer to maintain much-needed access to health care and food stamps. Must Read The bill’s changes to Medicaid include mandatory work requirements for many individuals aged 19 ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.Xeris Biopharma Holdings stock is taking a hit today. What’s weighing on XERS shares?Lawsuit Targets Two Pharmaceutical CompaniesThe lawsuit, filed by Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, targets unauthorized generic versions of Recorlev. The lawsuit names Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC as the ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv JPMorgan, Barclays, Fifth Third sued by investors for missing 'giant red flags' at Tricolor "Rather than risk a massive loss on their warehouse lines and forfeit the millions of dollars of fees and income derived from Tricolor's fraudulent enterprise, defendants responded by hiding what they had learned and sticking their heads in the sand," the complaint said. JPMorgan, Barclays and Cincinnat ...

Financial Overview - Oryzon Genomics reported a strong cash position of $33.3 million (€28.4 million) at the end of 2025, following a financial turnaround with over $60 million secured in the first half of 2025 [4][14]. - Research and development (R&D) expenses for Q4 2025 were $5.2 million, totaling $14.8 million for the year, compared to $2.1 million and $8.7 million in the same periods of 2024 [12]. - General and administrative expenses were $1.7 million for Q4 2025 and $5.6 million for the full year, up from $0.9 million and $3.7 million in 2024 [12]. - The net loss for Q4 2025 was $2.1 million, with a total net loss of $6.7 million for the year, compared to losses of $1.1 million and $4.6 million in 2024 [13][14]. Oncology Developments - Iadademstat, Oryzon's lead oncology program, is currently involved in seven ongoing trials, with six sponsored by the National Cancer Institute (NCI) or leading U.S. institutions [4][6]. - The drug has shown a 100% overall response rate (ORR) in first-line acute myeloid leukemia (AML) trials, with no dose-limiting toxicities reported [4][8]. - Preliminary data from the ALICE-2 Phase Ib trial indicated a 100% ORR and 90% strict complete remission (CR) in newly diagnosed AML patients [8]. - A new Phase Ib trial of iadademstat in combination with immune checkpoint inhibitors and radiotherapy for extensive-stage small cell lung cancer (ES-SCLC) has commenced [8]. CNS Program Updates - Oryzon has appointed Dr. Rolando Gutierrez as Chief Medical Officer for CNS programs, enhancing its medical and regulatory capabilities [4][7]. - The company is preparing for a protocol resubmission to the FDA for the Phase III PORTICO-2 trial in aggression in Borderline Personality Disorder (BPD) [13]. - Oryzon is expanding its Phase IIb schizophrenia trial into additional EU countries and finalizing preparations for a new Phase II trial in aggression in autism spectrum disorder (ASD) [7][13]. Intellectual Property and Future Trials - Oryzon has strengthened its intellectual property protection for iadademstat, with a patent application granted in Japan, expected to remain in force until at least 2040 [9]. - The company plans to initiate a clinical trial for iadademstat in essential thrombocythemia (ET) following EMA approval [8]. - Oryzon's earlier stage program, ORY-4001, a selective HDAC6 inhibitor, is progressing through IND enabling studies for neurological diseases [11].

(Bloomberg) --When smoke rapidly engulfed his home in Oregon, retired firefighter Fred Cuozzo rushed away in his pickup truck and nearly died from swerving around flames. All but one structure on his rural 16-acre lot was destroyed by the 2020 fire.Processing ContentFive and a half years later, Cuozzo, 80, is still waiting for more than $6 million that was awarded by a jury that determined Berkshire Hathaway Inc. utility PacifiCorp's equipment caused the fire. Cuozzo's award is a tiny part of billions of do ...

Group 1 - CME Group is currently experiencing a technical issue that has led to a suspension of trading [1][2] - The company is actively working to resolve the issue as quickly as possible [1][2] - There are concerns from users regarding potential market manipulation and calls for an investigation into the matter [1][2] Group 2 - Ernest Hoffman is a Crypto and Market Reporter for Kitco News with over 15 years of experience in market news [3] - He has a background in journalism and has contributed to various media and educational organizations [3]

Core Viewpoint - Evertz Technologies Limited is set to release its third quarter 2026 financial results on March 4, 2026, at 4:00 p.m. (EDT) [1] Group 1: Financial Results Announcement - The company will hold a conference call with financial analysts to discuss the results on March 4, 2026, at 5:00 p.m. (EDT) [2] - Media and other interested parties can join the conference call in listen-only mode, accessible by dialing 1-289-514-5100 or Toll-Free (North America) 1-800-717-1738 [2] - A rebroadcast of the conference call will be available until April 4, 2026, accessible at 1-289-819-1325 or Toll-Free 1-888-660-6264, with the pass code for the rebroadcast being 66926 [3] Group 2: Company Overview - Evertz Technologies Limited designs, manufactures, and markets video and audio infrastructure solutions [3] - The company's solutions are utilized by various sectors including television broadcast, telecommunications, professional audio-visual, government, military, enterprise, and new media [3] - Evertz's offerings support complex multi-channel digital environments, enabling high-definition, Ultra HD, and high dynamic range formats, which help customers generate additional revenue while reducing costs through efficient signal routing and management [3]

Key Takeaways CEG is one of the largest U.S. nuclear operators, generating about 10% of the nation's carbon-free power.AEP plans $72B in 2026-2030 investments and is exploring Small Modular Reactors.CEG posts 20.77% ROE and 29.1% one-year gains, topping AEP's profitability and stock rise.The demand for clean electricity is increasing rapidly due to several factors, including the expansion of large AI-driven data centers, rapid urbanization, industrial growth, rising global temperatures that boost air condit ...

Key Takeaways Bloom Energy has a marginal edge over FuelCell based on earnings growth and better ROIC. BE's EPS is seen up 81.58% in 2026 and 108.46% in 2027, with ROIC at 4.12%.FuelCell's shares gained 35.2% in three months while Bloom Energy rallied 54.4%. The companies belonging to the Zacks Alternate Energy-Other industry present an attractive long-term investment opportunity as global demand for clean energy continues to accelerate. Green and low-carbon hydrogen can play a crucial role in decarbonizing ...